Befovacimab (Anti-TFPI)
Befovacimab (Anti-TFPI) (A2779-GRP)
Products
Description
Befovacimab (anti-TFPI) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitors (TFPI) with the potential to be used in  haemophilia A/B research. MW: 143.24 kD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2779 |
| Target | Thrombin |